Biotron Limited Expands Portfolio with Sedarex Acquisition and AU$2.5 million Capital Raise

Biotron Limited (ASX: BIT) has announced the acquisition of Sedarex Limited, a company owning global patents for SedRx™, a next-generation anaesthetic offering superior safety and cognitive recovery. SedRx is a reformulated version of Althesin, a previously successful anaesthetic withdrawn due to formulation issues, now replaced with an FDA-approved solubilising agent. The acquisition, valued at AU$1.5 million in Biotron shares plus milestone-linked shares, marks Biotron’s strategic diversification into neuroscience while continuing antiviral research. Supported by Peak Asset Management, Biotron secured commitments for a AU$1 million placement and will conduct a AU$1.5 million rights issue at AU$0.003 per share with attaching options. Funds will advance SedRx’s regulatory approvals, develop its neurological indications, and support ongoing antiviral and corporate activities. Completion of the acquisition and rights issue is expected by December 2025, transforming Biotron into a broader clinical-stage biotechnology company.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com